title: Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors.
authors: Department of Medicine, Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, University of Liège, 4000, Liège, Belgium. andre.scheen@chu.ulg.ac.be.|Department of Medicine, Unit of Clinical Pharmacology, CHU Liège, University of Liège, Liège, Belgium. andre.scheen@chu.ulg.ac.be.
authors: A J
authors: AJ
authors: Scheen
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005060:Europe; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D012955:Societies, Medical; D016896:Treatment Outcome; D014481:United States
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin